TissUse grants first Smart Hair Transplant (SHT) License in Japan

For the first time, TissUse has granted development and distribution rights of its existing Smart Hair Transplant (SHT) technology to J. Hewitt, a Japan-based biopharmaceutical company focused on creating transformative regenerative medicine for aesthetic surgery.

Under the terms of this agreement, TissUse grants J. Hewitt an exclusive license in Japan for the development of novel cell-based hair regeneration therapies leveraging TissUse’s SHT technology and expertise.


“We are excited to work with TissUse and the strategic license agreement is testament to our confidence in the value of the TissUse technologies. We look forward to a successful relationship with TissUse as we contribute to the further development of its SHT technology,” says Dr. Jon Knight, CEO of J. Hewitt.

“This agreement synergizes the complementary ideas, know-how and experience of both companies. We are very much looking forward to enhancing TissUse’s highly innovative SHT approach through this collaboration,” explains Dr. Uwe Marx, CEO of TissUse.

Technical and financial details of the collaboration were not disclosed.

About J. Hewittwww.jhewitt.co.jp

J.Hewitt was established in Tokyo in February 1977 as an importer and distributor of medical devices and equipment. A management buyout completed in July 2004 by Jon Knight, redirected the company’s focus as a world pioneer into the field of aesthetic regenerative medicine. Dr. Knight conceptualized and invented the use of Platelet-Rich Plasma (PRP) for wrinkle augmentation and first in world use in humans for nasolabial folds, tear troughs, crow feet, and other facial wrinkles was performed in early 2005 and has been widely copied and is now a common therapy offered by most cosmetic surgeons and aesthetic dermatologists.

Über die TissUse GmbH

TissUse is a vibrant growth company, based in Berlin, Germany, which has developed a unique "Multi-Organ-Chip" platform that provides unparalleled preclinical insight on a systemic level using human tissues. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse’s Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.

TissUse’s Multi-Organ-Chips have been utilized in a large variety of applications including drug development, cosmetics, food and nutrition and consumer products since 2012.

TissUse is additionally applying its platform and know-how to develop spin-off programmes in a variety of tissue and organ repair areas, starting with the cosmetic market of hair transplants.

Firmenkontakt und Herausgeber der Meldung:

TissUse GmbH
Oudenarder Str. 16
13347 Berlin
Telefon: +49 (30) 513026400
http://www.tissuse.com

Ansprechpartner:
Sarah Tremmel
Business Development Manager
Telefon: +49 (30) 513026-400
Fax: +49 (30) 513026-401
E-Mail: info@tissuse.com
Für die oben stehende Pressemitteilung ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel